Literature DB >> 10103208

Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

C M Bebear1, J Renaudin, A Charron, H Renaudin, B de Barbeyrac, T Schaeverbeke, C Bebear.   

Abstract

Five clinical isolates of Mycoplasma hominis from three different patients were examined for resistance to fluoroquinolones; some of these isolates were probably identical. All five isolates harbored amino acid substitutions in the quinolone resistance-determining regions of both DNA gyrase (GyrA) and topoisomerase IV (ParC or ParE). Furthermore, the novobiocin MIC for three isolates showed a significant increase. This is the first characterization of fluoroquinolone-resistant clinical mycoplasma isolates from humans.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10103208      PMCID： PMC89234     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase.

Authors:  A Contreras; A Maxwell
Journal:  Mol Microbiol       Date:  1992-06       Impact factor: 3.501

2.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

3.  Sequencing analysis reveals a unique gene organization in the gyrB region of Mycoplasma hominis.

Authors:  S A Ladefoged; G Christiansen
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

4.  Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.

Authors:  C M Bébéar; A Charron; J M Bové; C Bébéar; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

5.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  The region of the parE gene, homologous to the quinolone-resistant determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates.

Authors:  J Ruiz; S Casellas; M T Jimenez de Anta; J Vila
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

7.  Increase in resistance of Mycoplasma hominis to tetracyclines.

Authors:  M C Cummings; W M McCormack
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

8.  Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.

Authors:  C M Bébéar; H Renaudin; A Charron; J M Bové; C Bébéar; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

10.  Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; L M Yamanaka; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191
View more
  35 in total

1.  Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.

Authors:  A K Reinhardt; C M Bébéar; M Kobisch; I Kempf; A V Gautier-Bouchardon
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones.

Authors:  C M Bébéar; H Renaudin; A Charron; M Clerc; S Pereyre; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

3.  In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively.

Authors:  D Gruson; S Pereyre; H Renaudin; A Charron; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  In vitro susceptibilities of Mycoplasma hyopneumoniae field isolates.

Authors:  J Vicca; T Stakenborg; D Maes; P Butaye; J Peeters; A de Kruif; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Increased expression of two multidrug transporter-like genes is associated with ethidium bromide and ciprofloxacin resistance in Mycoplasma hominis.

Authors:  S Raherison; P Gonzalez; H Renaudin; A Charron; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Authors:  I Lysnyansky; I Mikula; I Gerchman; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

7.  Levels of Mycoplasma genitalium Antimicrobial Resistance Differ by Both Region and Gender in the State of Queensland, Australia: Implications for Treatment Guidelines.

Authors:  E L Sweeney; E Trembizki; C Bletchly; C S Bradshaw; A Menon; F Francis; J Langton-Lockton; G R Nimmo; D M Whiley
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

8.  Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.

Authors:  S Pereyre; P Gonzalez; B De Barbeyrac; A Darnige; H Renaudin; A Charron; S Raherison; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 9.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Molecular characterization of acquired enrofloxacin resistance in Mycoplasma synoviae field isolates.

Authors:  I Lysnyansky; I Gerchman; I Mikula; F Gobbo; S Catania; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.